Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial

Qing Zhou, Ming Chen, Ou Jiang, Yi Pan, Desheng Hu, Qin Lin, Gang Wu, Jiuwei Cui, Jianhua Chang, Yufeng Cheng, Cheng Huang, Anwen Liu, Nong Yang, Youling Gong, Chuan Zhu, Zhiyong Ma, Jian Fang, Gongyan Chen, Jun Zhao, Anhui Shi, Yingcheng Lin, Guanghui Li, Yunpeng Liu, Dong Wang, Rong Wu, Xinhua Xu, Jianhua Shi, Zhihua Liu, Na Cui, Jingru Wang, Qiang Wang, Ran Zhang, Jason Yang, Yi-Long Wu